Breathing as One: The Expanded Role of IL-5 Inhibition in Patient Care for Chronic Rhinosinusitis with Nasal Polyps and Severe Asthma

This promotional symposium was funded by GSK and is intended for healthcare professionals only. 

Disclaimer: The views and opinions expressed in this symposium are those of the individual speakers and do not necessarily reflect those of GSK or EMJ. UK Prescribing Information and Adverse Event Reporting Information for Nucala (mepolizumab) can be found here. Adverse event reporting can also be found at the end of this webpage. For Healthcare Professionals outside of the UK, please refer to your Local Prescribing Information and Adverse Event Reporting Guidelines.

While recent research on the role of IL-5 suggests an impact on disease processes mentioned in this presentation, the definitive MoA has not been established yet. Any clinical implications of such research findings are yet to be established and do not imply a therapeutic benefit beyond those approved in the SmPC.

This symposium captures the symposium held at the European Academy of Allergy and Clinical Immunology (EAACI) Congress on 13 June, 2025 in Glasgow, UK. Expert speakers discussed the burden of disease in severe asthma and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps), the concept of the unified airway, and emerging evidence on IL-5 inhibition as a therapeutic strategy. The session included clinical trial data and real-world evidence on mepolizumab, patient case studies, and panel discussion on optimising care pathways.

1. Department of Allergy, University Hospital La Paz, Madrid, Spain
2. EAACI Patient Organisations Committee Chair, Istanbul, Türkiye
3. Münsterstraße Clinic, Düsseldorf, Germany